期刊档案
Therapeutic Advances in Medical Oncology
— · ISSN 1758-8340 · ONCOLOGY-
数据可追溯 · letpub-v6 · 更新于 2026-08-25期刊简介
研究范围与定位
Therapeutic Advances in Medical Oncology delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in medical oncology, providing an online forum for rapid dissemination of recent research and perspectives in this area.The journal is dedicated to publishing clinical research. We do not publish preclinical research, including basic laboratory research and animal studies.Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). Therapeutic Advances in Medical Oncology conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.The journal adheres to a blind review process in which the reviewer’s name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees; and Online First publication is usually within 3 weeks of Acceptance.
结构化分区
学科分区明细
不同版本、大类与小类分别展示,不将不同评价口径合并为一个分区值。
《新锐期刊分区表》( 2026年3月发布)
2026-03 · 2 个学科记录
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 2区 |
| 小类 | 肿瘤学ONCOLOGY | 3区 |
期刊分区表( 2025年3月升级版)
2025-03 · 2 个学科记录
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 2区 |
| 小类 | 肿瘤学ONCOLOGY | 3区 |
期刊分区表( 2023年12月旧的升级版)
2023-12 · 2 个学科记录
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 2区 |
| 小类 | 肿瘤学ONCOLOGY | 3区 |
期刊档案
出版与身份
- 期刊ISSN
- 1758-8340
- E-ISSN
- 1758-8359
- 是否OA开放访问
- Yes
- 通讯方式
- SAGE PUBLICATIONS LTD, 1 OLIVERS YARD, 55 CITY ROAD, LONDON, ENGLAND, EC1Y 1SP
- 出版商
- SAGE Publications Inc.
- 出版国家或地区
- ENGLAND
- 出版语言
- English
- 出版周期
- Continuous publication
- 出版年份
- 2009
期刊档案
研究范围
- 期刊简介
- Therapeutic Advances in Medical Oncology delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in medical oncology, providing an online forum for rapid dissemination of recent research and perspectives in this area.The journal is dedicated to publishing clinical research. We do not publish preclinical research, including basic laboratory research and animal studies.Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). Therapeutic Advances in Medical Oncology conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.The journal adheres to a blind review process in which the reviewer’s name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees; and Online First publication is usually within 3 weeks of Acceptance.
- 涉及的研究方向
- ONCOLOGY-
期刊档案
指标与活跃度
- 2025-2026最新IF(数据来源于网友提供)
- 注册或登录后,查看IF
- 实时影响因子
- 截止2026年5月06日:4.11
- 2025-2026自引率
- 2.4%点击查看自引率趋势图
- 五年IF(数据来源于网友提供)
- 4.095数据由网友[坦然可爱]收集提供
- h-index
- 34
- CiteScore ( 2026年6月最新版)
- CiteScoreSJRSNIPCiteScore排名6.201.4161.070学科分区排名百分位大类:Medicine小类:OncologyQ1100 / 428 76%
- 年文章数
- 267点击查看年文章数趋势图
- Gold OA文章占比
- 99.85%
- 研究类文章占比:文章 ÷(文章 + 综述)
- 76.40%
期刊档案
分区、收录与风险
- WOS期刊JCR分区 ( 2025-2026年最新版)
- 注册或登录后,查看WOS分区等级
- 期刊分区表预警名单
- 2026年03月发布的新锐学术版:不在预警名单中2025年03月发布的2025版:不在预警名单中2024年02月发布的2024版:不在预警名单中2023年01月发布的2023版:不在预警名单中2021年12月发布的2021版:不在预警名单中2020年12月发布的2020版:不在预警名单中
- SCI期刊收录coverage
- Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE)Scopus (CiteScore)Directory of Open Access Journals (DOAJ)中科院的全球OA期刊索引(OAJ)
- PubMed Central (PMC)链接
- 访问官方页面 ↗
期刊档案
投稿与评审
来源与统计口径
来源:LetPub 原始详情页 ↗。投稿经验仅展示聚合统计,不公开第三方正文或用户标识。当前聚合样本:暂无。